TY - JOUR AU - Mazraeh, Reihaneh AU - Azizi-Soleiman, Fatemeh AU - Jazayeri, Seyed Mohammad Hosein Mousavi AU - Noori, Seyyed Mohammad Ali PY - 2019/03/20 Y2 - 2024/03/28 TI - Effect of inulin-type fructans in patients undergoing cancer treatments: A systematic review: Effect of inulin-type fructans in cancer treatments JF - Pakistan Journal of Medical Sciences JA - Pak J Med Sci VL - 35 IS - 2 SE - Systematic Review DO - 10.12669/pjms.35.2.701 UR - https://www.pjms.org.pk/index.php/pjms/article/view/701 SP - AB - Background and Objective: Current studies give us inconsistent results regarding the inulin consumption in cancer patients. The results of to-date studies are summarized in this systematic review.Methods: Web of Science (Science citation index expanded), PubMed (Medline), Embase and CENTRAL Science direct, Google scholar, Scopus and Cochrane were searched. Cochrane Collaboration’s ‘Risk of Bias’ tool was used to assess the quality of included articles.Results: Our search yielded 2652 studies after the elimination of duplicates. Three randomized controlled trials (RCTs), reporting results from 197 patients, were eligible for inclusion in the present systematic review. Risk of bias in these studies was assessed as high and moderate.Conclusion: The available evidence is inconclusive regarding the effect of inulin and oligofructose on cancer outcomes. Nonetheless, possible inulin positive effects including improved stool consistency after abdomen radiotherapy and increased stool butyrate content which is involved in controlling tumor cells proliferation and apoptosis should not be denied. Further research is needed in this area before strong conclusions can be drawn.How to cite this:Mazraeh R, Azizi-Soleiman F, Jazayeri SMHM, Noori SMA. Effect of inulin-type fructans in patients undergoing cancer treatments: A systematic review. Pak J Med Sci. 2019;35(2):575-580. doi: https://doi.org/10.12669/pjms.35.2.701This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ER -